INSM

InsmedD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$260.00

+150.3% vs current

Most likely

Base case

55%

Probability

Target price

$205.00

+97.4% vs current

B-

Bear case

20%

Probability

Target price

$110.00

+5.9% vs current

AI sentiment snapshot

Latest data as of 2026-02-20

AI commentary

Market tone is cautiously constructive: consensus median above the anchor implies upside, but wide target dispersion signals execution risk and potential volatility on news.

RankAlpha Sentiment AI - 2026-02-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-21eventRegulatory/label updateHigh impact

A regulatory decision or label change would be material to valuation; we assume a conservative near-term window for planning [#SERP-3].

2026-05-21catalyst12-month analyst target revisionsHigh impact

Consensus median sits well above the current price; upgrades or target increases from coverage analysts could trigger a near-term re-rating [#SERP-1].

2027-02-20catalystCommercial uptake and revenue cadenceHigh impact

Sustained sales growth, broader adoption or improved reimbursement would materially re-rate the stock over a 12-month horizon [#SERP-4].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-20 • Updated nightlySource: Internal modelMethodology